secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001520138-25-000223
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie appoints Amy Chappell and Kameel Farag to Board of Directors
-------------------------------------------------------------------

- Board expanded from 4 to 6 members; appointments effective July 17, 2025.
- Dr. Chappell: 25 years at Eli Lilly, led CNS drug development including Cymbalta; former CMO of Eliem Therapeutics.
- Mr. Farag: former CFO of Aspen Neuroscience (raised $150M+), SVP Finance at Ionis, Regional CFO at Amgen.
- BioVie advancing bezisterim Phase 2 trials for early Parkinson's (SUNRISE-PD) and long COVID (ADDRESS-LC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/0001520138-25-000223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013825000223/bivi-20250722_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-25-000223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer